« Return to News | Clinical Intelligence

ACORN reports positive research results

Friday, July 1, 2011 10:17 AM

Accelerated Community Oncology Research Network (ACORN) reported positive results of a large, double-blind, randomized phase IIb trial in patients with breast cancer. The study evaluated a drug regimen for the treatment of locally advanced or metastatic breast cancer. The regimen, NexavarR (sorafenib) tablets in combination with either Gemcitabine (GemzarR) or Capecitabine (XelodaR), found statistically significant improvement in progression-free survival.  Forty investigative sites enrolled 160 patients over a three-year period.

Lee S. Schwartzberg, M.D., FACP, president of ACORN and chief medical officer of The West Clinic in Memphis, Tenn., served as study co-chair. "This study was conceived as one of a suite of trials collectively evaluating the addition of Nexavar to chemotherapy in different advanced disease settings,” he said. “The results demonstrate activity for this antiangiogenic agent in patients who had progressed on bevacizumab-containing regimens."

The West Clinic was, along with Memorial Sloan Kettering Cancer Center, a high enrolling site. According to Kurt Tauer, M.D., FACP, chief of staff and principal investigator for the study at The West Clinic, "This trial was a high priority for the clinic due to the interest in adding biological agents to standard chemotherapy, and we are pleased to see the positive results."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.